Can a new pill take on brain cancer?

NCT ID NCT07739017

Not yet recruiting Disease control Sponsor: Olivia Newton-John Cancer Research Institute Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This early-stage trial tests an experimental drug called CT-179 in people with glioblastoma, an aggressive brain cancer. The study has two parts: one for patients whose cancer has returned, and another for newly diagnosed patients who will also receive radiation therapy. The main goal is to find the safest dose and understand how the drug behaves in the body, paving the way for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CT-179
What this could lead to: If successful, this could lead to a new treatment option for glioblastoma, a type of brain cancer with limited therapies.
What could go wrong: This is an early-phase trial, so the drug may not be effective or may cause unexpected side effects. The results will only establish a safe dose, not prove benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Austin Health

Heidelberg, Victoria, 3084, Australia
Royal Brisbane and Women's Hospital

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.